Clinical trials: Substance Dependence
Schizophrenia, Mood Disorders
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
The main purpose of this study is to determine if the multifaceted treatment for substance abuse in dual disordered patients is more effective in reducing drug use than a supportive control treatment.
- Conditions
- Schizophrenia, Mood Disorders, Substance Dependence
- Trial name
- NCT00295139
- Testing
- Behavioral Treatment for Substance Abuse in SPMI (BTSAS), Supportive Treatment in Addiction Recovery (STAR), Critical Time Intervention (CTI)
- Where
- 4 sites in United States
- Volunteers
- 293 people
- Sponsor
- University of Maryland, Baltimore
Drug Dependence
Extended Release Naltrexone for Opioid-Dependent Youth
The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).
- Trial name
- NCT01843023
- Testing
- Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
- Where
- 2 sites in United States
- Volunteers
- 288 people
- Sponsor
- Friends Research Institute, Inc.
Cocaine Dependence
Cocaine Use Reduction With Buprenorphine
The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence.
- Trial name
- CURB (NCT01402492)
- Testing
- Buprenorphine + Naltrexone
- Where
- 11 sites in United States
- Volunteers
- 302 people
- Sponsor
- University of California, Los Angeles
Alcohol Use Disorder (AUD), Alcohol Abuse
Neurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder
Background: Alcohol Use Disorder (AUD) is a complex psychiatric disorder, involving several brain areas and neurocircuits. Transcranial Direct Current Stimulation (tDCS) allows to stimulate superficial areas of brain using a weak…
- Conditions
- Alcohol Use Disorder (AUD), Alcohol Abuse, Alcohol Dependence, Alcohol-Related Disorders
- Trial name
- NCT04897295
- Testing
- Active transcranial Direct Current Stimulation
- Volunteers
- 30 people
- Sponsor
- ITAB - Institute for Advanced Biomedical Technologies
Substance Use Disorders, Substance Abuse
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.
- Conditions
- Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
- Trial name
- NCT03762798
- Testing
- The Bridge
- Where
- United States
- Sponsor
- The Cleveland Clinic
Drug Abuse, Drug Dependence
Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation
In France, the Afssaps is the body in charge of the evaluation of pharmacodependance. In order to fulfil its mission, the Afssaps has created a network of 11 Centres for Evaluation and Information on Pharmacodependance (CEIP)…
- Trial name
- NCT01052675
- Where
- 10 sites in France
- Volunteers
- 3,180 people
- Sponsor
- Nantes University Hospital
Substance Use Disorders, Opiate Dependence
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, \& Maguen, 2018) and the Substance Abuse…
- Conditions
- Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder
- Trial name
- NCT03971097
- Testing
- Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Pittsburgh
Addiction, Opioid Dependence
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
- Conditions
- Addiction, Opioid Dependence, Opioid Withdrawal
- Trial name
- NCT03813095
- Testing
- APH-1501
- Volunteers
- 32 people
- Sponsor
- Aphios
Methamphetamine Dependence, Methamphetamine Withdrawal
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine use has escalated in recent years. Methamphetamine use has also spread throughout the country. Although much information has been gathered on the treatment of cocaine abuse, very little information has been…
- Trial name
- NCT00653263
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Opioid Dependence, Opioid Intoxication
Naloxone to TReatment Entry in the Emergency Setting
The study tests a structured referral process for opioid overdose survivors, from pre-hospital emergency care to long-term treatment of the individual's substance use-related disorder.
- Conditions
- Opioid Dependence, Opioid Intoxication, Substance Use Disorders
- Trial name
- N-TREE (NCT03368794)
- Testing
- Active treatment referral of opioid overdose survivors to long-term treatment, Control
- Where
- Sweden
- Sponsor
- Anders C Håkansson
Alcohol Dependence, Alcohol Abuse
Carisbamate as a Potential Treatment for Alcohol Dependence
The purpose of this study is to determine the effects of treatment with carisbamate compared to treatment with placebo, on alcohol-induced stimulant and subjective effects in non-treatment seeking alcohol-dependent human…
- Conditions
- Alcohol Dependence, Alcohol Abuse, Substance Abuse
- Trial name
- NCT02435381
- Testing
- Carisbamate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Baylor College of Medicine
Methamphetamine Dependence in Remission
The Efficacy of N-acetylcysteine Versus Placebo for the Treatment of Metamphetamine Withdrawal Symptoms
Up to date, no approved medications are available for the treatment of methamphetamine addiction. Recently, N-acetylcysteine is recently being studied for methamphetamine withdrawal.
- Trial name
- NCT04405193
- Testing
- N-acetyl cysteine
- Where
- Indonesia
- Volunteers
- 66 people
- Sponsor
- Melva Louisa
Substance Use Disorder, Cocaine Dependence
Cannabidiol and Cocaine Craving/Dependence
In this study, the investigators seek to evaluate the effects of cannabidiol (CBD) on cocaine craving and relapse. Cocaine addiction is characterized by compulsive substance use and repetitive urges to consume the drug even after…
- Conditions
- Substance Use Disorder, Cocaine Dependence, Withdrawal From Addictive Substance; Detoxification
- Trial name
- CBD (NCT02559167)
- Testing
- Cannabidiol
- Where
- Canada
- Volunteers
- 79 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Heroin Dependence, Opioid-Related Disorders
Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1
The purpose of this study is to compare the Standard Medical Management (SMM) vs. SMM enhanced with additional education about addiction and recovery (Enhanced Medical Management, EMM)
- Conditions
- Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
- Trial name
- NCT00023283
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Yale University
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is…
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
- Trial name
- NCT03583138
- Testing
- buprenorphine
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Yale University
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
HIV, Buprenorphine, and the Criminal Justice System
The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design.
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
- Trial name
- STRIDE (NCT01550341)
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Drug Dependence
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
The purpose of this study is to compare the effectiveness of different levels of counseling (intensive outpatient versus standard outpatient) on treatment outcomes for African American adult patients receiving buprenorphine in 2…
- Trial name
- NCT01096550
- Testing
- Outpatient, Intensive Outpatient
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Friends Research Institute, Inc.
Dual Diagnosis, Cocaine Abuse
Abstinence-Linked Money Management Multisite
Randomized clinical trial comparing a money management-based intervention involving storage and management of client funds, substance abuse counseling, and risk reduction counseling to individualized drug counseling.
- Conditions
- Dual Diagnosis, Cocaine Abuse, Cocaine Dependence, Polysubstance Abuse
- Trial name
- NCT01327586
- Testing
- ATM, Individual Drug Counseling
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- Yale University
HIV, AIDS
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
Specific Aim: To conduct a randomized, placebo-controlled trial of extended release-naltrexone (XR-NTX) among Human Immunodeficiency Virus (HIV) infected prisoners meeting Diagnostic Statistical Manual IV (DSM-IV) criteria for…
- Conditions
- HIV, AIDS, Opioid Dependence, Drug Dependence
- Trial name
- NewHope (NCT01246401)
- Testing
- Extended-Release Naltrexone
- Where
- 3 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Yale University
Cocaine Dependence
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
Cocaine use disorders affect approximately 1.5 million Americans annually. Currently, there are no US Food and Drug Administration approved medications for treatment of cocaine dependence; however, both animal and human studies…
- Trial name
- NCT01953432
- Testing
- Doxazosin
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development